Trial Profile
A phase 2 pharmacokinetic trial of dovitinib (TKI258) in Asian and non-Asian patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2015
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Renal cancer
- Focus Pharmacokinetics
- 06 Dec 2015 New trial record